Article
Pharmacokinetic- pharmacodynamic analysis of the role of CYP2C19 genotypes in short-term rabeprazole-based triple therapy against Helicobacter pylori.
British journal of clinical pharmacology - 1 May 2009
Yang Jyh-Chin, Yang Yu-Fan, Uang Yow-Shieng, Lin Chun-Jung, Wang Teh-Hong
Abstract excerpt
AIMS: The aim was to explore the role of CYP2C19 polymorphism in short-term rabeprazole-based triple therapy against Helicobacter pylori infection. METHODS: Patients with H. pylori infection were tested for CYP2C19 genotype as poor metabolizers (PMs) or extensive metabolizers (EMs, homozygous EM or heterozygous EM) and given rabeprazole for 7 days. Antibiotics (clarithromycin and amoxicillin) were given on days...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
